PARP1 and early-onset autosomal dominant Alzheimer disease: Several FDA-approved PARP1 inhibitors, initially proposed for use in tumor treatment, have also demonstrated therapeutic effects in models of non-cancerous diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, diabetes, and myocardial infarction [17,18,19,20,21,22].